JPWO2022118966A1 - - Google Patents

Info

Publication number
JPWO2022118966A1
JPWO2022118966A1 JP2022567009A JP2022567009A JPWO2022118966A1 JP WO2022118966 A1 JPWO2022118966 A1 JP WO2022118966A1 JP 2022567009 A JP2022567009 A JP 2022567009A JP 2022567009 A JP2022567009 A JP 2022567009A JP WO2022118966 A1 JPWO2022118966 A1 JP WO2022118966A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567009A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022118966A1 publication Critical patent/JPWO2022118966A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022567009A 2020-12-04 2021-12-03 Pending JPWO2022118966A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020201756 2020-12-04
PCT/JP2021/044526 WO2022118966A1 (ja) 2020-12-04 2021-12-03 細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物

Publications (1)

Publication Number Publication Date
JPWO2022118966A1 true JPWO2022118966A1 (cg-RX-API-DMAC7.html) 2022-06-09

Family

ID=81853347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567009A Pending JPWO2022118966A1 (cg-RX-API-DMAC7.html) 2020-12-04 2021-12-03

Country Status (2)

Country Link
JP (1) JPWO2022118966A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022118966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024043242A1 (cg-RX-API-DMAC7.html) * 2022-08-23 2024-02-29

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511764A (ja) * 1995-01-11 1997-11-25 三進製藥株式會社 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物
JP2008253188A (ja) * 2007-04-04 2008-10-23 Tokyo Univ Of Science エンドサイトーシス依存性dna取り込み抑制剤、エンドサイトーシス依存性dna取り込み促進剤、ウイルス感染阻害剤、ウイルス感染予防剤、及びウイルス感染促進剤、並びに、遺伝子マーカー、モノクローナル抗体、ハイブリドーマ、及びそれらの使用方法。
JP2013116858A (ja) * 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Bdnf様低分子化合物を含有する治療薬
WO2014192865A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 フェニルピペラジン誘導体
WO2019183536A1 (en) * 2018-03-22 2019-09-26 Research Foundation Of The City University Of New York Modulation of neuronal nkcc1 as a therapeutic strategy for spasticity and related disorders
WO2020069194A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511764A (ja) * 1995-01-11 1997-11-25 三進製藥株式會社 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物
JP2008253188A (ja) * 2007-04-04 2008-10-23 Tokyo Univ Of Science エンドサイトーシス依存性dna取り込み抑制剤、エンドサイトーシス依存性dna取り込み促進剤、ウイルス感染阻害剤、ウイルス感染予防剤、及びウイルス感染促進剤、並びに、遺伝子マーカー、モノクローナル抗体、ハイブリドーマ、及びそれらの使用方法。
JP2013116858A (ja) * 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Bdnf様低分子化合物を含有する治療薬
WO2014192865A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 フェニルピペラジン誘導体
WO2019183536A1 (en) * 2018-03-22 2019-09-26 Research Foundation Of The City University Of New York Modulation of neuronal nkcc1 as a therapeutic strategy for spasticity and related disorders
WO2020069194A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DE LA CRUZ, G. G. ET AL.: "Intensified Microwave-Assisted N-Acylation Procedure - Synthesis and Activity Evaluation of TRPC3 Ch", SYNLETT, vol. 28, JPN6022005262, 2017, pages 695 - 700, ISSN: 0005789258 *
GAO, N. ET AL.: "Angiotensin II induces calcium-mediated autophagy in podocytes through enhancing reactive oxygen spe", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 277, JPN6022005256, 2017, pages 110 - 118, ISSN: 0005789255 *
HAO, F. ET AL.: "Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer’s mic", LIFE SCIENCES, vol. Vol. 264, 118624, JPN6022005258, 21 October 2020 (2020-10-21), pages 1 - 10, ISSN: 0005789256 *
LIU, Z. ET AL.: "TRPC6-Mediated Ca2+ Entry Essential for the Regulation of Nano-ZnO Induced Autophagy in SH-SY5Y Cell", NEUROCHEMICAL RESEARCH, vol. 45, JPN6022005254, 9 April 2020 (2020-04-09), pages 1602 - 1613, ISSN: 0005789254 *
SAWAMURA, S. ET AL.: "Screening of Transient Receptor Potential Canonical Channel Activators Identifies Novel Neurotrophic", MOLECULAR PHARMACOLOGY, vol. 89, JPN6021051514, 2016, pages 348 - 363, ISSN: 0005789253 *
SHRIVASTAVA, A. ET AL.: "Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk betw", MOLECULAR CANCER THERAPEUTICS, vol. 10, no. 7, JPN6022005260, 2011, pages 1161 - 1172, ISSN: 0005789257 *
YAMASHITA, T.: "Ca2+-dependent regulation of synaptic vesicle endocytosis", NEUROSCIENCE RESEARCH, vol. 73, JPN6022005263, 2012, pages 1 - 7, ISSN: 0005789259 *

Also Published As

Publication number Publication date
WO2022118966A1 (ja) 2022-06-09

Similar Documents

Publication Publication Date Title
BR112022013461B1 (pt) Fechamento deslizante para um recipiente metalúrgico e seu uso
CN305632361S (zh) 筋膜枪(极致款g1)
CN305587415S (zh) 吸尘器玩具
CN305578553S (zh) 茶几(gncj01)
CN305606738S (zh) 电竞椅扶手
CN305572882S (zh) 保鲜碗
CN305582510S (zh) 加湿器(复古)
CN305541842S (zh) 电磁炉(816)
CN305564025S (zh) 椅子(轮胎)
CN305574673S (zh) 柴油雾化喷射器
CN305554443S (zh) 桌面净化器
CN305533460S (zh) 防水盒(黑色不透明升级款)
CN305567329S (zh) 电动自行车(6)
CN305561285S (zh) 标签
CN305536801S (zh) 游戏键盘鼠标转换器
CN305532928S (zh) 磨豆机
CN305535832S (zh) 垃圾桶(zl-001)
CN305534749S (zh) 锅煲(福猫)
CN305590638S (zh) 沙发架(6688)
CN305586241S (zh) 汽车散热器格栅
CN305531203S (zh) 锁架
CN305533170S (zh) 运动休闲鞋底
CN305528385S (zh) 太空杯(幸运珠)
CN305555464S (zh) 台灯
CN305609379S (zh) 挂坠(nu2052)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260625